Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 934 000 KRW 0.21% Market Closed
Market Cap: 66.5T KRW
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Samsung Biologics Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Samsung Biologics Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Net Income (Common)
â‚©1T
CAGR 3-Years
45%
CAGR 5-Years
34%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Net Income (Common)
-â‚©164m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Net Income (Common)
â‚©32.4B
CAGR 3-Years
104%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Net Income (Common)
-â‚©8.7B
CAGR 3-Years
19%
CAGR 5-Years
3%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Net Income (Common)
-â‚©2.9B
CAGR 3-Years
58%
CAGR 5-Years
-22%
CAGR 10-Years
9%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Net Income (Common)
-â‚©8.7B
CAGR 3-Years
25%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Samsung Biologics Co Ltd
Glance View

Market Cap
66.5T KRW
Industry
Life Sciences Tools & Services

Samsung Biologics Co., Ltd. is a prominent player in the biopharmaceutical industry, and its story reflects the growing importance of biologics in modern medicine. Founded in 2011 and headquartered in Incheon, South Korea, the company has quickly established itself as a leader in contract development and manufacturing services (CDMO) for biopharmaceuticals. With state-of-the-art facilities and a strong emphasis on quality and innovation, Samsung Biologics partners with global pharmaceutical companies to produce cutting-edge therapies, from monoclonal antibodies to recombinant proteins. The company's commitment to enhancing biotechnology capabilities is further highlighted by its substantial investments in expanding production capacity and capabilities, positioning it as a trusted partner in the fiercely competitive biomanufacturing landscape. For investors, Samsung Biologics represents a compelling opportunity in the rapidly growing biopharmaceutical sector, driven by increasing demand for effective therapies and the advancements in biologic drug development. The company has consistently demonstrated impressive financial performance, with significant revenue growth propelled by long-term contracts and collaborations with major biotech firms. Its strategic location in South Korea, coupled with a strong focus on regulatory compliance and sustainability, adds to its appeal as a stable and forward-thinking investment. As the global landscape continues to shift toward biologic treatments, Samsung Biologics is well-positioned to capitalize on this trend, making it an attractive prospect for those looking to invest in the future of healthcare innovation.

Intrinsic Value
467 896.37 KRW
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Samsung Biologics Co Ltd's Net Income (Common)?
Net Income (Common)
1T KRW

Based on the financial report for Jun 30, 2024, Samsung Biologics Co Ltd's Net Income (Common) amounts to 1T KRW.

What is Samsung Biologics Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
34%

Over the last year, the Net Income (Common) growth was 25%. The average annual Net Income (Common) growth rates for Samsung Biologics Co Ltd have been 45% over the past three years , 34% over the past five years .

Back to Top